The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000745347p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
4/06/2026
Date registered
Help: Date registered
22/06/2026
Date last updated
Help: Date last updated
22/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
22/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Evaluating pre-surgical non-invasive brain stimulation for improving post-surgical outcomes in those with endometriosis: A pilot study
Scientific title
Evaluating pre-surgical non-invasive brain stimulation for improving post-surgical symptoms in those undergoing laparoscopic surgery for endometriosis: A pilot study
Additional trial identifiers [1] 317465 0
Nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Endometriosis 342166 0
Condition category
Condition code
Reproductive Health and Childbirth 338282 338282 0 0
Other reproductive health and childbirth disorders
Anaesthesiology 338447 338447 0 0
Pain management

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Participants will receive a pre-operative course of home-based transcranial direct current stimulation (tDCS) targeting the primary motor cortex (M1). The intervention will be self-administered at home following a 1 hour in-person training session, provided by a member of the research team.

tDCS Stimulation will be delivered using the Soterix mini-CT Stimulator (Soterix Medical Inc., New York, USA) with a coded study mode. The device delivers a constant current via two pre-saturated SNAPpad saline-soaked sponge electrodes (5x7cm) fitted into a custom headpiece. Electrode positions are set up at the training session and participants are not required to adjust them during the home-based phase.

During active tDCS, a constant current of 2mA will be applied for 20 minutes. The anode electrode will be placed over M1 contralateral to the side of dominant pelvic pain, positioned according to the International 10-20 system (position C3 or C4). The reference cathode will be placed over the ipsilateral supraorbital region.

Participants will complete five consecutive daily sessions, finishing 3-5 days prior to their planned surgery. Each day, participants will receive a single-use treatment code to input into the device to commence stimulation. Device settings cannot be modified by the participant. Participants will receive a completion code after the 20-minute session is finished, that they will send to the research team to confirm session completion
Intervention code [1] 334287 0
Treatment: Devices
Intervention code [2] 334361 0
Prevention
Description of the comparator or control
The sham condition will involve identical procedures, except the sham program delivers no actual stimulation beyond a mild current for the first 15 seconds (providing an initial ‘itching’ sensation).

Participants will complete five consecutive daily sessions, finishing 3-5 days prior to their planned surgery. Each day, participants will receive a single-use treatment code to input into the device to commence stimulation. Device settings cannot be modified by the participant. Participants will receive a completion code after the 20-minute session is finished, that they will send to the research team to confirm session completion
Control group
Placebo

Outcomes
Primary outcome [1] 345661 0
Pelvic pain intensity
Timepoint [1] 345661 0
Baseline, 2 weeks after intervention commencement, 3 months after intervention completion
Primary outcome [2] 345742 0
Feasibility - this will be assessed as a composite outcome. This includes recruitment rate, adherence, dropout rate, and reporting of adverse events.
Timepoint [2] 345742 0
Recruitment assessed at the end of recruitment period Adherence assessed throughout the study period Dropout rate assessed at the end of the study period Adverse event: continuously monitored throughout the intervention
Secondary outcome [1] 462743 0
The Central Sensitization Inventory (CSI)
Timepoint [1] 462743 0
Baseline, 2 weeks after intervention commencement, 3 months after intervention completion

Eligibility
Key inclusion criteria
Participants must meet all of the following criteria:
• Aged 18 years or over.
• Diagnosis of endometriosis based on clinical examination and/or imaging findings (transvaginal ultrasound or MRI).
• No prior surgery for endometriosis.
• No abdominal surgery in the previous six months.
• Attending the gynaecology clinic, pre-operation planning and having laparoscopic excision endometriosis surgery at The Royal Hospital for Women, Randwick.
• Surgery scheduled at least four weeks from the anticipated date of consent.
• Residing in Australia during the study period.
• Willing and able to provide informed consent and adhere to the protocol.
• Able to understand and communicate in English.
• Has reliable internet or mobile access for remote monitoring and daily questionnaire completion.
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Healthy volunteers
No
Key exclusion criteria
Participants presenting with any of the following will be excluded:
Endometriosis and surgical exclusions:
• Comorbid acute or chronic pain condition other than endometriosis that, in the opinion of the investigative team, would confound assessment of outcomes.
• Any endometriosis-related surgery planned or undertaken in the six months prior to enrolment.
• tDCS safety contraindications (assessed via TMS/tDCS Adult Safety Screen questionnaire). Developed by Rossi and Rossini, a copy of the document is provided in the HREA attachments. This covers:
• History of epilepsy or seizure disorder.
• Electronic or metal implants in the head (e.g., cochlear implants, deep brain stimulators, intracranial metal plates or clips).
• Cognitive impairment that would preclude safe independent self-administration of the tDCS device.
• Current use of benzodiazepines (known to interfere with tDCS-induced neuroplasticity).
• Opioid use exceeding a daily morphine equivalent dose of 40mg (known to interfere with sensorimotor and cognitive function in ways that may confound outcomes).
• Current or past history of a significant neurological disorder (e.g., stroke, traumatic brain injury, demyelinating disease).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation concealment will be maintained through REDCap's randomisation module. The randomisation schedule is accessible only to the REDCap system; research team members with enrolment privileges cannot view upcoming allocations. Treatment assignment is revealed to the relevant team member only at the point of randomisation, after the participant's eligibility and consent have been confirmed and recorded. This sequence cannot be reversed or pre-empted.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer-generated random sequence
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 322035 0
University
Name [1] 322035 0
Global Challenge Lead Grant (Fostering Healthy Communities), Western Sydney University
Country [1] 322035 0
Australia
Primary sponsor type
University
Name
Western Sydney University
Address
Country
Australia
Secondary sponsor category [1] 324913 0
None
Name [1] 324913 0
Address [1] 324913 0
Country [1] 324913 0
Other collaborator category [1] 283974 0
Hospital
Name [1] 283974 0
Royal Hospital for Women, Randwick
Address [1] 283974 0
Country [1] 283974 0
Australia

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320566 0
University of Western Sydney Human Research Ethics Committee
Ethics committee address [1] 320566 0
Ethics committee country [1] 320566 0
Australia
Date submitted for ethics approval [1] 320566 0
29/05/2026
Approval date [1] 320566 0
Ethics approval number [1] 320566 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150902 0
Dr Rocco Cavaleri
Address 150902 0
Western Sydney University, Narellan Rd & Gilchrist Dr, Campbelltown NSW 2560
Country 150902 0
Australia
Phone 150902 0
+610246203994
Fax 150902 0
Email 150902 0
Contact person for public queries
Name 150903 0
Rocco Cavaleri
Address 150903 0
Western Sydney University, Narellan Rd & Gilchrist Dr, Campbelltown NSW 2560
Country 150903 0
Australia
Phone 150903 0
+610246203994
Fax 150903 0
Email 150903 0
Contact person for scientific queries
Name 150904 0
Rocco Cavaleri
Address 150904 0
Western Sydney University, Narellan Rd & Gilchrist Dr, Campbelltown NSW 2560
Country 150904 0
Australia
Phone 150904 0
+610246203994
Fax 150904 0
Email 150904 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.